Narayana Q1: consol revenue +78% on UK buyout, but margins squeeze PAT growth to just 5% YoY

Narayana Hrudayalaya's Q1 FY27 print is a tale of two statements. On a consolidated basis revenue jumped 78% YoY to ₹2,683.6 Cr, but that surge is almost entirely inorganic — the first full quarter that consolidates UK-based Practice Plus Group (acquired November 2025 for GBP 188.8mn) plus the now-larger Narayana Health Insurance arm. Consolidated PAT rose only 5.4% YoY to ₹207.3 Cr and actually fell 7.5% sequentially, because the acquisition and new-centre costs absorbed the topline. Net profit margin collapsed to 7.72% from 13.01% a year ago, and operating margin to 17.50% from 22.36% — the clearest number in the filing.

The underlying India business, however, is healthy: standalone revenue grew 16.3% YoY to ₹1,097.1 Cr and standalone PAT rose 57.8% to ₹137.9 Cr (EPS ₹6.79 vs ₹4.30), with an ~12.6% net margin. The >3% divergence between the standalone and consolidated growth stories is the whole point of this quarter — readers seeing standalone's +58% PAT must not confuse it with the group's +5%; the gap is the UK and insurance drag. Segmentally, the 'Others' (insurance) segment loss widened to ₹62.5 Cr and the seven overseas subsidiaries reviewed by other auditors together lost ₹15.1 Cr after tax — the loss-making pieces diluting an otherwise strong core.

The stock went into the print at ₹2,029.2, up 2.2% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

Consolidated EPS ₹10.20 (vs ₹9.65 YoY) — no exceptional item this quarter (prior FY26 had a ₹50.95 Cr year-end labour-code exceptional, so YoY comparison is clean).

This outcome matches, rather than contradicts, management's own Q4 FY26 guidance: they explicitly told the last concall that new-centre losses and acquisition-integration costs would moderate short-term profitability, with margin improvement expected only over the medium-to-long term as UK integration and ramp-ups mature. So the margin compression is the guided path, not a surprise. On the Street side, the pre-result focus was squarely on margin stabilisation post-UK integration rather than a headline PAT beat/miss — no firm published consensus PAT estimate surfaced, so vsStreet is left unknown; the OPM slip to 17.5% is the metric the August 3 concall will be judged on.